Expand BEAM Menu
BEAM MENU

BEAM Latest Press Releases

-- April 1, 2026 --

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine Globe Newswire 5:12 PM

-- March 25, 2026 --

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development Globe Newswire 7:00 AM

-- February 24, 2026 --

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) Globe Newswire 7:01 AM
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street Globe Newswire 7:00 AM

-- February 23, 2026 --

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program Globe Newswire 4:00 PM

-- January 11, 2026 --

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition Globe Newswire 5:00 PM

-- December 18, 2025 --

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 4:01 PM

-- December 9, 2025 --

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PRNewswire 11:58 AM

-- December 6, 2025 --

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes